FGF2 and neoplasm: FGF2-B9 tumors developed larger blood vessels than HEC-1-B tumors as a consequence of FGF2 overexpression and [NSIS6S]-[NSIS]5 reduced the average vessel size by 51% in FGF2-B9 xenografts (Fig 5D).The fact that sunitinib reduced tumor growth (Fig 5A) as well as FGF2-dependent and -independent vasculature formation in FGF2-B9 tumors (Fig 5B and 5C) suggests that dodecasaccharide inhibitory potency against VEGF is insufficient to slow tumour growth through inhibition of angiogenesis or off-target effects of sunitinib are contributing to reduced tumour growth.